T2 Biosystems, Inc. (LON:0A57)

T2 Biosystems Company Description

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally.

Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.

The company also offers T2Dx Instrument, an instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens.

In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease.

T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

T2 Biosystems, Inc.

Country	United States
Founded	2006
Industry	In Vitro and In Vivo Diagnostic Substances
Employees	113
CEO	Craig Jalbert

Contact Details

Address: 101 Hartwell Avenue Lexington, Delaware 02421 United States
Phone	781 761 4646
Website	t2biosystems.com

Stock Details

Ticker Symbol	0A57
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2835

Key Executives

Name	Position
Craig Jalbert	Chief Executive Officer